Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti & Neptune Enter Into Transactional Arrangement & Sign Operational Agreements

GlobeNewswire January 7, 2016

MicroCap Report: Acasti (V.APO) jumps, Guestlogix (T.GXI) dives on accounting review

Stockhouse Editorial December 16, 2015

Acasti Provides Update on CaPre® Development Pathway

GlobeNewswire December 16, 2015

Acasti Granted Composition & Use Patent in Japan, Taiwan and Mexico

GlobeNewswire December 1, 2015

Acasti Announces Second Quarter Results

GlobeNewswire October 14, 2015

Acasti Announces 1-for-10 Reverse Stock Split

GlobeNewswire September 29, 2015

Acasti Announces Grant of Stock Options

GlobeNewswire August 19, 2015

Mario Paradis Appointed CFO of Neptune and Acasti

GlobeNewswire August 5, 2015

Acasti Announces First Quarter Results

GlobeNewswire July 13, 2015

Acasti Announces Grant of Stock Options

GlobeNewswire June 1, 2015

Acasti Announces Fourth Quarter and Fiscal Year Results

GlobeNewswire May 27, 2015

Acasti Announces New Board of Director Nominees for Election at Annual and Special Meeting of Shareholders

GlobeNewswire May 27, 2015

Acasti Receives Extension to Regain Compliance With NASDAQ Minimum Bid Price Rule

GlobeNewswire May 11, 2015

Acasti Announces Departure of Chief Financial Officer

GlobeNewswire April 29, 2015

Acasti Granted Composition & Use Patent in China

GlobeNewswire March 25, 2015

USPTO Issues Positive Decision That Triggers Royalty Payments to Neptune

GlobeNewswire March 23, 2015

Acasti Receives Full Data for Phase II TRIFECTA Trial

GlobeNewswire March 2, 2015

Dr. Tina Sampalis Appointed Medical Science Liaison for Neptune

GlobeNewswire February 5, 2015

Acasti Announces Third Quarter Results

GlobeNewswire January 13, 2015

Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements

GlobeNewswire November 11, 2014